31st May 2006 07:01
International Medical Devices PLC31 May 2006 International Medical Devices Plc Interim results for the period ended 28 February 2006 International Medical Devices Plc (INT.L) ('International Medical Devices' or'the Company'), a medical devices company involved in the design, development,manufacturing and marketing of safety needles, announces excellent progressduring the last 6 months. 28 Feb '06 28 Feb '05 28 Aug '05 £'000 £'000 £'000 Turnover 779 - -Gross Profit 264 - - Operating Profit/(loss):- acquisitions 43 - -- continuing operations (202) (89) (316) Loss after Tax (158) (85) (316) CEO Chris Thomas said, "International Medical Devices has enjoyed a verypositive start to the year. The latest acquisition, Response Medical Equipment,has started well, and is planning to introduce a number of new product lines toits portfolio. In the near future, I look forward to updating shareholders onthe progress of the launch of 'Clip-on', the company's pioneering safe needle,into the NHS." Highlights - Meddis acquisition continues to show healthy trading - Response Medical acquisition bedding in well - 'Clip-On' safety needle set for NHS trials during May and June - Initial feedback from NHS clinicians very positive for 'Clip-On' - Further potential acquisition opportunities identified Chairman's Statement I am pleased to report on the excellent progress made by International MedicalDevices Plc during the last 6 months. The Company has commenced the first stageof its corporate strategy which was outlined in the admission document issued inJuly 2005. This strategy is predicated upon exploiting the intellectualproperty rights acquired at that time. In September 2005, the company acquiredMeddis Limited (see below) and this acquisition was the first step towardsachieving the desired aim of creating routes to market for the productsavailable with the intellectual property rights. Results In the first half of the financial year, International Medical Devices hasfocused on developing and implementing its stated strategy. This 6 month periodreflects central costs of the holding Company for the full period, while alsoincorporating five months trading results from Meddis Limited. Turnover in thisperiod amounted to £779,000, with a loss on ordinary activities of £(158,000),with a resultant loss per share of £(0.0125). The Directors do not recommend adividend. Acquisition of Meddis Limited Meddis Limited was acquired in September 2005. Its primary customer focus isthe Acute Care sector, and the company supplies a portfolio of catheters andwound drainage products. The company also owns a patent for a catheterspecifically for children which was designed and developed by the company'sManaging Director. The Group's accounts include trading by Meddis Limited fromthe date of acquisition to the period end. The acquisition consideration wasmade up of £200,000 in cash and £200,000 in shares priced at 10p each, pluscosts. Post balance sheet events In April 2006, post the period end, the Group acquired RME Holdings Limited andits subsidiary, Response Medical Equipment Limited. Response Medical EquipmentLimited supplies a variety of products to all NHS trust hospitals in England.This acquisition, combined with Meddis Limited, provides the group with a verywidespread and effective route to market for both these companies' existingproducts, and those available as a result of the acquisition of the intellectualproperty rights noted above. Equity funding has been raised in order to finance the acquisition of RMEHoldings Limited and its subsidiary. Post the balance sheet date the Group hasraised equity funding as detailed in Note 6 of the Interim Financial Statements. Board Changes On 29th November 2005, Mike Acheson joined the Board as Finance Director, he wasalso appointed Company Secretary on 5th April 2006. John Butler and MatthewRoot both joined the Board on 25th April 2006, following the acquisition of RMEHoldings Limited as noted under Post Balance sheet events. Prospects The group is now entering a period of positive growth, through its acquisitionsand through the exploitation of the intellectual property rights. One excitingproduct, "Clip-On", a safe needle device, is going to be trialed at five majorNHS hospitals in the UK during May and June 2006. Initial feedback fromclinicians has been very positive. Following the acquisitions noted above, thegroup is now focusing its revenue streams in three main market sectors, beingEmergency Care, Acute Care, and Aged Care. The group will continue to seekadditional acquisition opportunities to develop and maximise its position withinthese market sectors. Lindsay C.S. SanfordChairman26th May 2006 International Medical Devices PlcInterim Financial Statements 28 February 2006Consolidated Profit and Loss Accounts Unaudited Unaudited Audited 6 months to 6 months Period to 28 Feb 2006 to 31 Aug 2005 28 Feb 2005 £ £ £Turnover:-acquisitions 779,364 - - Cost of Sales (515,344) - - ---------- ---------- -------------Gross Profit 264,020 - - Administrative expenses (422,924) (88,595) (322,564) ---------- ---------- -------------Operating Profit/(loss): - continuing operations (201,605) (88,595) (322,564) - acquisitions 42,701 - - ---------- ---------- ------------- (158,904) (88,595) (322,564)Interest receivable 1,080 3,162 6,497 ---------- ---------- -------------Loss on ordinary activities before taxation (157,824) (85,433) (316,067) Tax on loss on ordinary activities - - - ---------- ---------- -------------Loss on ordinary activities after taxation (157,824) (85,433) (316,067) ======= ======= =======Loss per share (0.01251) (0.008) (0.01249) Reconciliation of Movements of Shareholders' Funds Unaudited Unaudited Audited 6 months to 6 months Period to 28 Feb 2006 to 31 Aug 2005 28 Feb 2005 £ £ £ Loss for the Financial Period (157,824) (85,433) (316,067) Issue of Share Capital 20,000 160,000 1,244,934Premium on Issue 180,000 121,754 7,577,867 Expenses on issue - - (327,479) ---------- ---------- --------------Net Movement in Shareholders' funds 42,176 196,321 8,179,255 ---------- ---------- --------------Closing Shareholders' funds 8,221,431 196,321 8,179,255 ======== ======= ========== International Medical Devices PlcInterim Financial statements 28 February 2006Consolidated Balance Sheets Unaudited Unaudited Audited at 28 Feb at 28 Feb At 31 Aug 2006 2005 2005 £ £ £ Fixed Assets - Intangibles 8,231,650 - 7,952,800 - Tangibles 100,381 - - --------- ---------- ---------- 8,332,031 - 7,952,800Current Assets - Debtors 500,373 31,687 128,031 - Stock 212,352 - - - Cash at bank and in hand 76,995 189,450 363,299 --------- ---------- ---------- 789,720 221,137 491,330 Creditors falling due within one year (900,320) (24,816) (264,875) --------- ---------- ---------- Net Assets 8,221,431 196,321 8,179,255 ======= ======== ========Capital and reserves: - Issued Share Capital 1,264,934 160,000 1,244,934 - Share premium account 7,430,388 121,754 7,250,388 Profit and loss account (473,891) (85,433) (316,067) --------- ---------- ----------Equity Shareholders' Funds 8,221,431 196,321 8,179,255 ======= ====== ======= International Medical Devices PlcInterim Financial Statements 28 February 2006Consolidated Cash Flow Statements Unaudited Unaudited Audited 6 months 6 months Period to to to 31 Aug 28 Feb 28 Feb 2005 2006 2005 £ £ £ Operating loss (158,904) (88,595) (322,564)Depreciation 5,291 - - Increase in stocks (212,352) - -Increase in Debtors (372,342) (31,687) (128,031)Increase in Creditors 635,445 24,816 264,875 --------- ---------- -----------Net Cash outflow from operating activities (102,862) (95,466) (185,720) Returns on investments and servicingof financing Interest Received 1,080 3,162 6,497 Capital Expenditure and Financial Investment Purchase of Patents and Distribution Rights - - (7,952,800) Purchase of Company and associated costs- Goodwill (274,531) - -Purchase of fixed assets (109,991) - - --------- ---------- ----------- Net Cashflow before Financing (486,304) (92,304) (8,132,032) Financing Proceeds of share issues 200,000 (281,754) 8,822,801 Expenses on issuing of Share Capital - - (327,479) --------- ---------- -----------Decrease/Increase in net cash period (286,304) 189,450 363,299 ======= ====== ====== Notes to the Interim Financial Statements for the six months to 28 February2006. 1. The financial information contained in this interim statement for the 6 months ended 28 February 2006 is unaudited and does not comprise accounts within the meaning of s240 of the Companies Act 1985. The financial information for the full preceding period is based on the statutory accounts for the financial year ended 31 August 2005. 2. The financial statements have been prepared under UK GAAP and the accounting policies of the company as set out in its Annual Report and Accounts to 31 August 2005. During the Interim Period, Meddis Limited was acquired. As a result, the Group now prepares Consolidated Financial Statements. The comparative Interim Financial Statements for the period ended 28 February 2005 and the period ended 31 August 2005 reflect the performance of the holding company only. 3. The Consolidated financial statements include the financial statements of the Company and its subsidiary to 28 February 2006. Assets and liabilities that exist at the date of acquisition are recorded at their fair values reflecting their condition at that date. Purchased goodwill arising on consolidation represents the excess of the fair value of the consideration given, plus associated costs, for a business over the fair value of the assets acquired. Goodwill arising on acquisition is capitalised as an intangible fixed asset. 4. Meddis Limited was acquired on 15 September 2005, and the Consolidated Financial Statements therefore include Meddis Limited's turnover and costs from that date to 28 February 2006. 5. Meddis Limited acquisition consideration included the issue of 2,000,000 shares at a price of 10 pence per share, a nominal value of 1 pence per share, with the balance being attributed to the share premium account. 6. The Earnings per Ordinary Share in this interim period is calculated by reference to the loss of £(157,824) and the weighted average number of 126,160,000 shares in issue during this period. The period ending 28 February 2005 incurred a loss of £(85,433) and the weighted average number of shares was 10,560,440. For the year to 31 August 2005, a loss of £(316,067) was incurred and the weighted average number of shares amounted to 25,313,003. 7. Post Balance Sheet Events: (i) Post period end, the company raised £2,656,200 additional equity for cash, by issuing 53,124,000 shares, at a price of 5 pence per share, before costs. In additional, the company raised £667,687 additional equity for cash through the conversion of 17,805,000 warrants at a price of 3.75 pence per share in accordance with the terms and conditions of the warrants granted, before costs. Following the fund raising, all outstanding warrants lapsed, with no further rights attached. The Company also issued shares to a value of £2,800,000 at 7 pence per share, and £250,000 at 5 pence per share, for vendor consideration. A further 2,681,940 shares have been issued at 5 pence in settlement of professional advisers' fees. (ii) On 5 April 2006, RME Holdings Limited and its subsidiary Response Medical Equipment Limited were acquired by the company, for a consideration made up of cash shares and loan notes, for a total of £6,300,000. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Intelliam Ai